Graff, Julie N
Beer, Tomasz M
Alumkal, Joshi J
Slottke, Rachel E
Redmond, William L http://orcid.org/0000-0002-2572-1731
Thomas, George V
Thompson, Reid F
Wood, Mary A
Koguchi, Yoshinobu
Chen, Yiyi
Latour, Emile
Bergan, Raymond C
Drake, Charles G
Moran, Amy E
Clinical trials referenced in this document:
Documents that mention this clinical trial
344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
https://doi.org/10.1136/jitc-2020-sitc2020.0344
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
https://doi.org/10.1136/jitc-2020-000642
Documents that mention this clinical trial
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
https://doi.org/10.1136/jitc-2020-sitc2020.0346
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
https://doi.org/10.1136/jitc-2020-000642
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Documents that mention this clinical trial
Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
https://doi.org/10.1136/ijgc-2022-003719
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
579-D Multiplex imaging of ovarian carcinoma reveals spatial cell interaction patterns predictive of immunotherapy responses
https://doi.org/10.1136/jitc-2023-sitc2023.0579-d
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
https://doi.org/10.1136/jitc-2020-000642
Funding for this research was provided by:
Merck
Bloomberg Kimmel Institute